about
Adipose tissue macrophages promote myelopoiesis and monocytosis in obesityOver-expressing the soluble gp130-Fc does not ameliorate methionine and choline deficient diet-induced non alcoholic steatohepatitis in mice.Tumor progression locus 2 (Tpl2) deficiency does not protect against obesity-induced metabolic diseaseThe dual-specificity phosphatase 2 (DUSP2) does not regulate obesity-associated inflammation or insulin resistance in mice.PKR is not obligatory for high-fat diet-induced obesity and its associated metabolic and inflammatory complications.Glucose-6-phosphate dehydrogenase contributes to the regulation of glucose uptake in skeletal muscle.Targeting gp130 to prevent inflammation and promote insulin action.Adipose tissue inflammation in glucose metabolism.Macrophage polarization in obesity and type 2 diabetes: weighing down our understanding of macrophage function?Blocking IL-6 trans-signaling prevents high-fat diet-induced adipose tissue macrophage recruitment but does not improve insulin resistance.Neutrophil-derived S100 calcium-binding proteins A8/A9 promote reticulated thrombocytosis and atherogenesis in diabetes.Analysis of the liver lipidome reveals insights into the protective effect of exercise on high-fat diet-induced hepatosteatosis in mice.Leptin-deficient obesity prolongs survival in a murine model of myelodysplastic syndrome.Resolution of glucose intolerance in long-term high-fat, high-sucrose-fed mice.IL-18 Production from the NLRP1 Inflammasome Prevents Obesity and Metabolic Syndrome.Fetuin B Is a Secreted Hepatocyte Factor Linking Steatosis to Impaired Glucose Metabolism.Evidence for a Non-leptin System that Defends against Weight Gain in OverfeedingPPARγ deacetylation dissociates thiazolidinedione's metabolic benefits from its adverse effects.Defective cholesterol metabolism in haematopoietic stem cells promotes monocyte-driven atherosclerosis in rheumatoid arthritis
P50
Q33724394-3676E3FE-73C1-4A64-AC85-E11A2AC7F478Q33817373-D349ED9B-BCEF-405B-B1CC-746188F4DB33Q34305887-AB08EA38-95CE-4F61-9E1B-D91E6B47D5B9Q34465742-AE991CED-799B-440D-8053-0F13B31051D8Q36549536-B01C1FAD-8B99-4CED-82C0-7D13B6BA8FC6Q37368731-D6E533D3-96CC-44CC-89FD-576B2FE9DA3BQ38134113-C4851C3B-28B5-49DD-B0E5-130C512E97ECQ38139293-1051ECCD-F95D-4216-BAE7-25E521A714F4Q38259566-16FEA3D9-7871-4C29-B518-893314ED5538Q41299746-40CD8961-216B-40C5-8CDE-9F82E4D3C8B1Q42180113-1E89FC30-42CC-4D8B-8FC9-93EA674C1E09Q46767755-1ADD5BDA-56CB-4AC3-BEEA-457690A56A71Q49681927-EBFC4E4A-B5FA-4A64-947A-D5D008F517B4Q50762714-D5E815F0-3BFE-4DED-A5DA-5B01CFA9E37FQ52900648-4405DE1B-BAED-49CA-8408-2434525D87B0Q53265229-FE4A5930-1682-44C7-ACBF-FD55BEB79898Q61844670-A3098ADE-1431-40C9-BFC6-7D3E79A8CD65Q64926407-6162B4BF-4158-4B4B-80A9-D14C876F98ACQ89113492-B374DB79-0A7F-432D-A31E-DCB366E01A2D
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Michael J Kraakman
@ast
Michael J Kraakman
@en
Michael J Kraakman
@es
Michael J Kraakman
@nl
type
label
Michael J Kraakman
@ast
Michael J Kraakman
@en
Michael J Kraakman
@es
Michael J Kraakman
@nl
prefLabel
Michael J Kraakman
@ast
Michael J Kraakman
@en
Michael J Kraakman
@es
Michael J Kraakman
@nl
P106
P1153
55250237800
P31
P496
0000-0002-5755-0447